Search results: Found 4

Listing 1 - 4 of 4
Sort by
Immunomodulatory Effects of Drugs for Treatment of Immune-Related Diseases

Author:
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889452880 Year: Pages: 108 DOI: 10.3389/978-2-88945-288-0 Language: English
Publisher: Frontiers Media SA
Subject: Medicine (General) --- Allergy and Immunology
Added to DOAB on : 2018-02-27 16:16:44
License:

Loading...
Export citation

Choose an application

Abstract

More than 90% of diseases possess immunological abnormalities. Disorders such as inflammation, hypersensitivity, autoimmunity and immunodeficiency are simple examples of how the immune system misinterprets its surroundings and goes awry. Multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel diseases, among many others are manifestations of immune cells attacking normal tissues. On the other hand, damping the immune system leads to diseases such as cancer, AIDS, and severe combined immunodeficiency. The last ten years witnessed an explosion in developing drugs that target the immune system. Several novel monoclonal antibodies have been approved for treatment of various diseases confirming that personalized medicine approach is robust in combating diseases. Hence, the future holds great promise for using personalized and targeted medicine rather than generalized medications that, in most circumstances, proven to be ineffective and characteristically exert side effects. Approaches such as generating novel adjuvants that can stimulate the immune system without harmful side effects, targeting inflammatory cytokines and chemokines, harnessing and activating innate immune cells such as natural killer cells or dendritic cells, are examples of future approaches to treat autoimmune diseases, AIDS, and various forms of cancer resulting from chronic inflammation. More recently, targeting immune checkpoint molecules have shown therapeutic response against lung cancer and melanoma. Identifying molecules involved in autophagy is another example of how personalized medicine might help treat patients with refractory asthma and autoimmune diseases. This topic introduces the reader to these novel approaches of manipulating the immune system and developing targeted therapeutic strategies for treatment of various diseases.

The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine

Authors: ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889195435 Year: Pages: 140 DOI: 10.3389/978-2-88919-543-5 Language: English
Publisher: Frontiers Media SA
Subject: Oncology --- Medicine (General)
Added to DOAB on : 2016-01-19 14:05:46
License:

Loading...
Export citation

Choose an application

Abstract

Lung cancer is the leading cause of cancer related mortality in Canada and USA. Majority of the patients present in advanced stage of the disease and of these only about 2% will be alive at 5 years. NSCLC is the most common form of lung cancer, accounting for approximately 87% of cases. Systemic chemotherapies have been used to treat metastatic NSCLC for decades, but the improvements of outcomes have reached a plateau. Recent advances in understanding signalling pathways for malignant cells, their interconections,the importance of various receptors and biomarkers and the interplay between various oncogenes have led to the development of targeted treatments that are improving both efficacy and safety of the treatments. Knowledge about the advantages of treatments with the targeted agents in metastatic NSCLC is growing rapidly. Combining various targeted agents or sequencing them properly will be important in the era of personalised medicine and overcoming development of the resistence to various targeted agents will be challenging. The importance of a team work,from the diagnosis through various treatments, to supportive care, from the interventional radiologists, pneumologists or surgeons, who have to obtain a satisfactory tumor tissue specimen, to pathologists, radiation and medical oncologists, to supportive care specialists, will be described in our publications. We will cover completely present and future approaches to personalised medicine in this rapidly evolving field of metastatic NSCLC.

MicroRNA as Biomarkers in Cancer Diagnostics and Therapy

Author:
ISBN: 9783039212491 / 9783039212507 Year: Pages: 166 DOI: 10.3390/books978-3-03921-250-7 Language: eng
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Science (General) --- Biology --- Microbiology
Added to DOAB on : 2019-08-28 11:21:27
License:

Loading...
Export citation

Choose an application

Abstract

This Special Issue celebrates the 25th anniversary of the discovery of the first microRNA. The size of the microRNome and complexity of animal body plans and organ systems suggests a role for microRNAs in cell fate determination and differentiation. More than 2000 sequences have been proposed to represent unique microRNA genes in humans, with an increasing number of mechanistic roles identified in developmental, physiological, and pathological processes. Thus, dysregulation of a few key microRNAs can have a profound global effect on the gene expression and molecular programs of a cell. This great potential for clinical intervention has captured the interest and imagination of researchers in many fields. However, very few fields have been as prolific as the field of cancer research. This Special Issue provides but a glimpse of the large body of literature of microRNA biology in cancer research, containing 4 original research studies and 4 review articles that focus on specific hematologic or solid tumors in disease. Collectively, these articles highlight state-of-the-art approaches and methodologies for microRNA detection in tissue, blood, and other body fluids in a range of biomarkers applications, from early cancer detection to prognosis and treatment response. The articles also address some of the challenges regarding clinical implementation.

Fungal Infections in Immunocompromised Hosts

Authors: ---
ISBN: 9783038977162 Year: Pages: 212 DOI: 10.3390/books978-3-03897-717-9 Language: eng
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Microbiology --- Biology --- Science (General)
Added to DOAB on : 2019-04-05 10:34:31
License:

Loading...
Export citation

Choose an application

Abstract

This book is a printed edition of the Special Issue Fungal Infections in Immunocompromised Hosts that was published in JoF

Keywords

Candida auris --- Aspergillus fumigatus --- antifungal resistance --- multidrug resistance --- mechanisms of antifungal resistance --- liver disease --- hepatic impairment --- invasive fungal infection --- antifungal agent --- antifungal drug --- toxicity --- Immunotherapy --- invasive aspergillosis --- Aspergillus fumigatus --- fungal infections --- innate immunity --- adaptive immunity --- cell therapy --- cytokine therapy --- taxonomy --- fungal nomenclature --- phylogenetics --- species complex --- invasive fungal infections --- mycoses --- immune reconstitution inflammatory syndrome --- fungal immunity --- prognostic risk model --- prediction models --- risk score --- invasive mold disease --- hematological malignancy --- risk assessment --- antifungal stewardship --- paracoccidioidomycosis --- HIV --- cancer --- lymphoma --- kidney transplant --- TNF inhibitors --- literature review --- MALDI-ToF MS --- yeast --- fungus --- AIDS --- IRIS --- cat-transmitted sporotrichosis --- immunocompromised hosts --- mycoses of implantation --- sporotrichosis --- Sporothrix brasiliensis --- Sporothrix schenckii --- subcutaneous mycoses --- invasive fungal infection --- non-culture-based diagnostics --- aspergillosis --- candidiasis --- Aspergillus PCR --- galactomannan --- lateral flow --- beta-d-glucan --- T2 Candida --- candidemia --- Candida meningoencephalitis --- (1?3)-?-d-glucan --- T2Candida --- PCR --- liposomal amphotericin B --- micafungin --- anidulafungin --- Aspergillus --- anti-fungal agents --- hematological malignancies

Listing 1 - 4 of 4
Sort by
Narrow your search